bluebird bio, Inc.
bluebird bio, Inc. (BLUE) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · BLUE · as of Jun 9, 2026
Key Statistics
Explore bluebird bio, Inc. Data
blue stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 37 · Buy rate: 37.8%
The BLUE analyst consensus is Hold, based on ratings from 37 Wall Street analysts over the past 3 months. The average 12-month price target is $13.69, representing +175.45% upside from the current price of $4.97.
Competitors & Peers
blue competitorsBLUE
ALVR
ERYP
GRNA
KRON
MGTAStock Performance
Full HistoryAbout bluebird bio, Inc.
bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating ge…
what is bluebird bio, inc. · blue stock overview · bluebird bio, inc. company profile · who is bluebird bio, inc. ceo · blue NASDAQ · bluebird bio, inc. headquarters · bluebird bio, inc. business segments
About Stock Overview & Key Data
bluebird bio, Inc. (BLUE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 19, 2013. As of the latest trading session, BLUE stock price is $4.97, with a market capitalization of $48.7M. The stock has returned -73.08% over the past 12 months and -42.81% year-to-date.
According to 37 Wall Street analysts, the consensus rating for bluebird bio, Inc. stock is Hold, with an average 12-month price target of $13.69. In fiscal year 2024, bluebird bio, Inc. reported revenue of $83.8M and net income of -$240.7M. For detailed data — including bluebird bio, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, bluebird bio, Inc. (BLUE) stock price is $4.97. The stock is traded on NASDAQ under the ticker symbol BLUE. The 52-week range is $3.20 – $28.60.